WO2022265052A1 - 育毛剤 - Google Patents

育毛剤 Download PDF

Info

Publication number
WO2022265052A1
WO2022265052A1 PCT/JP2022/024018 JP2022024018W WO2022265052A1 WO 2022265052 A1 WO2022265052 A1 WO 2022265052A1 JP 2022024018 W JP2022024018 W JP 2022024018W WO 2022265052 A1 WO2022265052 A1 WO 2022265052A1
Authority
WO
WIPO (PCT)
Prior art keywords
hair
palmitoyl dipeptide
phytosphingosine
hair restorer
dipeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2022/024018
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
秀樹 高橋
荘太 中村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adjuvant Holdings Co Ltd
Original Assignee
Adjuvant Holdings Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adjuvant Holdings Co Ltd filed Critical Adjuvant Holdings Co Ltd
Priority to CN202280054887.5A priority Critical patent/CN117794509A/zh
Priority to KR1020247001997A priority patent/KR20240023616A/ko
Priority to JP2023530384A priority patent/JPWO2022265052A1/ja
Priority to US18/571,529 priority patent/US20240285500A1/en
Priority to TW111122674A priority patent/TW202317076A/zh
Publication of WO2022265052A1 publication Critical patent/WO2022265052A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A61K2800/592—Mixtures of compounds complementing their respective functions
    • A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18

Definitions

  • the present invention relates to a hair restorer. More specifically, it relates to a hair restorer containing palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine, palmitoyl dipeptide-5 diaminohydroxybutyric acid, and phytosphingosine.
  • Hair growth repeats growth and shedding according to a hair cycle (hair cycle) consisting of a growth phase, a regression phase, and a resting phase.
  • the symptoms of androgenetic alopecia are that the balance of the hair cycle is lost due to some cause, the period of growth period is shortened, the proportion of telogen hair is increased, and the hair becomes vellus (downy hair).
  • Histologically it has been reported that the size of anagen hair follicles is smaller than that of healthy scalp, the development of dermal papilla is poor, and the capillary network surrounding hair follicles is reduced (Non-Patent Document 1).
  • hair restorers that improve hair growth and hair type/hair quality.
  • active ingredients that contribute to the regulation of the hair cycle, which is the life cycle of hair, have been proposed and are being marketed as hair restorers.
  • vascular endothelial growth factor is a growth factor that acts specifically on vascular endothelial cells isolated from the culture medium of pituitary foliculo-stellate (stellate follicle) cells, and promotes the proliferation of vascular endothelial cells. It is known that adenosine promotes the angiogenesis process and enhances vascular permeability. It is clear that when adenosine acts on human dermal papilla cells, it promotes the expression of vascular endothelial growth factor (VEGF). (see Non-Patent Document 2).
  • Minoxidil has been found to promote the expression of vascular endothelial growth factor (VEGF) when acting on dermal papilla cells (see Non-Patent Document 3).
  • VEGF vascular endothelial growth factor
  • Non-Patent Document 3 its medicinal use in Japan is limited to men's alopecia at the prime of life, and it has not fully satisfied the needs of a wide range of consumers who desire hair growth effects and hair type/hair quality improvement effects.
  • Non-Patent Document 4 Non-Patent Document 4
  • palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid significantly increased hair shaft elongation speed and maximum hair shaft length, and blood vessels in dermal papilla cells. It has an excellent hair-restoring effect such as promoting the expression of endothelial growth factor (VEGF), and has been found to be useful as an active ingredient of hair restorers and scalp care agents (see Patent Document 4).
  • VEGF endothelial growth factor
  • Phytosphingosine is known as a component of cosmetic raw materials (see Patent Document 5). However, there is no report on the hair growth effect of phytosphingosine.
  • An object of the present invention is to provide a hair restorer having an excellent hair growth effect.
  • the present inventors have found that the use of phytosphingosine as an active ingredient can exhibit hair growth activity, and palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine and palmitoyl
  • dipeptide-5 diaminohydroxybutyric acid and phytosphingosine as active ingredients, a stronger hair growth activity can be exhibited than when palmitoyl dipeptide-5 diaminohydroxybutyric acid or phytosphingosine is used.
  • the present inventors have found that it is possible to complete the present invention.
  • a first means of the present invention for solving the above problems is characterized by containing palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine, palmitoyl dipeptide-5 diaminohydroxybutyric acid, and phytosphingosine as active ingredients. It is a hair restorer.
  • the second means of the present invention for solving the above problems is characterized by containing palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid as active ingredients, combined with phytosphingosine It is a hair restorer for
  • a third means of the present invention for solving the above problems is a combination of palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid, characterized by containing phytosphingosine as an active ingredient. It is a hair restorer for
  • the fourth means of the present invention for solving the above problems is the hair restorer according to any one of the first to third means of the present invention, which is used for promoting hair shaft growth or hair growth. is.
  • a fifth means of the present invention for solving the above-mentioned problems is the hair restorer according to any one of the first to fourth means of the present invention, which is used for improving hair shaft elongation speed. is.
  • the sixth means of the present invention for solving the above problems is the hair restorer according to any one of the first to fourth means of the present invention, which is used for improving the maximum length of hair shafts. is.
  • the seventh means of the present invention for solving the above problems is the hair restorer according to any one of the first to fourth means of the present invention, which is used for increasing the diameter of the hair shaft. be.
  • the eighth means of the present invention for solving the above problems is the hair restorer according to any one of the first to fourth means of the present invention, which is used for increasing the number of hairs. .
  • the ninth means of the present invention for solving the above problems is the hair restorer according to any one of the first to eighth means of the present invention, which is a solution.
  • a tenth means of the present invention for solving the above problems is the hair restorer according to any one of the first to ninth means of the present invention for hair, bristles, eyebrows and/or eyelashes. is an agent.
  • the eleventh means of the present invention for solving the above problems is a step of incorporating palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine, palmitoyl dipeptide-5 diaminohydroxybutyric acid, and phytosphingosine into a formulation as active ingredients.
  • a method for producing a hair restorer characterized by having
  • the twelfth means of the present invention for solving the above problems is characterized by comprising a step of incorporating palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid into a formulation as active ingredients. , a method for producing a hair restorer for combined use with phytosphingosine.
  • the thirteenth means of the present invention for solving the above problems is palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine, palmitoyl dipeptide-5, characterized by comprising a step of incorporating phytosphingosine as an active ingredient in a formulation.
  • the fourteenth means of the present invention for solving the above problems is a formulation containing palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine, palmitoyl dipeptide-5 diaminohydroxybutyric acid, and a formulation containing phytosphingosine, It is a hair restorer kit.
  • the fifteenth means of the present invention for solving the above problems is a hair restorer for combined use with phytosphingosine, comprising a formulation containing palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid. is a kit.
  • the sixteenth means of the present invention for solving the above problems is a hair restorer for combined use with palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid, which contains a formulation containing phytosphingosine. is a kit.
  • the seventeenth means of the present invention for solving the above problems is characterized by administering palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine, palmitoyl dipeptide-5 diaminohydroxybutyric acid, and phytosphingosine as active ingredients. , is a hair growth method.
  • An eighteenth means of the present invention for solving the above problems is a hair restoration method comprising administering the hair restorer according to any one of the first to tenth means of the present invention to a subject. .
  • Another means of the present invention for solving the above problems is a scalp care agent containing palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine, palmitoyl dipeptide-5 diaminohydroxybutyric acid, and phytosphingosine as active ingredients.
  • a scalp care agent containing palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine, palmitoyl dipeptide-5 diaminohydroxybutyric acid, and phytosphingosine as active ingredients. It is a scalp symptom improvement method including administering to.
  • VEGF of dermal papilla cells containing palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine, palmitoyl dipeptide-5 diaminohydroxybutyric acid, and phytosphingosine as active ingredients. It is a production accelerator.
  • palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine, palmitoyl dipeptide-5 diaminohydroxybutyric acid and phytosphingosine are contained or used in combination as active ingredients of a hair restorer that is an external preparation, so that hair and hair can be improved.
  • a hair restorer that is an external preparation, so that hair and hair can be improved.
  • An excellent hair restorer that exhibits the effects of promoting hair shaft growth, improving the speed of hair shaft elongation, improving the maximum length of the hair shaft, increasing the diameter of the hair shaft, and scalp care effects in hair such as hair, eyebrows and / or eyelashes, and A scalp care agent is provided.
  • FIG. 1 shows palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine, palmitoyl dipeptide-5 diaminohydroxybutyrate, phytosphingosine, and palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine, palmitoyl dipeptide-5 diaminohydroxybutyrate and palmitoyl dipeptide-5 diaminohydroxybutyrate in human dermal papilla cells.
  • Fig. 10 is a graph showing changes in VEGF gene expression levels due to phytosphingosine stimulation for 72 hours.
  • the active ingredient of the hair restorer and scalp care agent according to the present invention contains both palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine, palmitoyl dipeptide-5 diaminohydroxybutyric acid and phytosphingosine, or palmitoyl dipeptide-5 diaminobutyric acid. It consists of a combination of royl hydroxythreonine, palmitoyl dipeptide-5-diaminohydroxybutyric acid, and adenosine.
  • the concentrations of palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine, palmitoyl dipeptide-5 diaminohydroxybutyric acid, and phytosphingosine, which are active ingredients in the hair restorer and scalp care agent of the present invention, were 0 relative to the total hair restorer and scalp care agent. 0.001 to 20% by weight. More specifically, it is 0.005 to 10% by weight.
  • the hair restorer and scalp care agent of the present invention are pharmaceuticals, quasi-drugs, cosmetics including cosmetics for hair, lashes, eyebrows and/or eyelashes, and cosmetics for the scalp, and ointments, cataplasms, liniments, lotions, and liquids for external use. , dusting agents, creams, gels, milky lotions, hair tonics, hair sprays, microneedles, etc., and can be used as preparations having various dosage forms such as, but not limited to, these.
  • the hair restorer and scalp care agent of the present invention can be produced through a process of incorporating palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine, palmitoyl dipeptide-5 diaminohydroxybutyric acid, and phytosphingosine as active ingredients.
  • the hair restorer and scalp care agent for combined use with palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid of the present invention undergo a step of containing phytosphingosine as an active ingredient
  • a hair restorer and a scalp care agent for combined use with phytosphingosine can be produced through a step of incorporating palmitoyl dipeptide-5 diaminobutyroylhydroxythreonine and palmitoyl dipeptide-5 diaminohydroxybutyric acid as active ingredients.
  • a step of adding additives for formulation may be added.
  • dosage forms of those formulations may be in the same dosage form or a combination of different dosage forms, and may be provided as a kit for providing formulations of those dosage forms.
  • Components of these additives include, for example, excipients, stabilizers, flavoring agents, bases, dispersants, diluents, anionic surfactants, amphoteric surfactants, nonionic surfactants, cationic surfactants, Active agents, anionic polymers, nonionic polymers, ethylene oxide/propylene oxide block copolymers, alcohols, emulsifiers, percutaneous absorption enhancers, pH adjusters, preservatives, coloring agents, oils and fats, mineral oils, etc.
  • the hair restorer and scalp care agent of the present invention may further contain known ingredients having effects such as hair growth, hair restoration, and hair nourishing.
  • the dosage of the active ingredient per administration of the hair restorer and scalp care agent in the means of the present invention can be adjusted so that the effects of the hair restorer and scalp care agent of the present invention are exhibited.
  • the dosage can be, for example, 0.005 to 200 mg, specifically 0.05 to 100 mg, and more specifically 0.5 to 10 mg.
  • the administration frequency of the hair restorer and scalp care agent of the present invention can be once or multiple times so that the effects of the hair restorer and scalp care agent of the present invention are exhibited.
  • the frequency of administration of the hair restorer and scalp care agent of the present invention can be, for example, 1 to 6 times per day. Specifically, it can be 1 to 3 times per day, more specifically 1 to 2 times per day.
  • the hair restorer and scalp care agent of the present invention relate to promotion of hair shaft growth, hair growth and prevention of hair loss, preferably promotion of hair shaft growth and hair growth.
  • promoting hair shaft growth means improving the hair shaft elongation speed, improving the maximum hair shaft length, and/or increasing the hair shaft diameter.
  • hair growth means that hair growth has stopped at a site where hair does not grow (the hair shaft does not protrude from the epidermis) or where the number of hairs is small, or the ability to grow hair is reduced. It means to promote the growth of new hairs from the pores to increase the number of hairs, in particular, to shorten the resting phase in the hair cycle and / or to restart the stopped hair cycle. .
  • having a hair shaft growth promoting effect means acting favorably on hair shaft growth promotion, and the property showing the hair shaft growth promoting effect is referred to as “hair shaft growth promoting activity”.
  • has a hair growth effect means that it acts favorably on hair growth, and the property showing the hair growth effect is referred to as “hair growth promoting activity”.
  • hair loss refers to a phenomenon in which hair shafts fall out of pores, and specifically refers to an increase in inhibitory cytokines that inhibit cell proliferation and cell death. Attributes that demonstrate anti-hair loss efficacy are referred to as "anti-hair loss activity.”
  • anti-hair loss activity Attributes that demonstrate anti-hair loss efficacy are referred to as "anti-hair loss activity.”
  • the term “has an anti-hair loss effect” means that the number of hair shafts falling out from pores is reduced through the inhibition or reduction of inhibitory cytokines and the suppression of cell death. It is a physiological phenomenon that is different from the attribute that indicates the hair effect.
  • scalingp symptoms means symptoms such as dandruff, rough skin, dry scalp, erythema, itching, and pimples.
  • scaling symptom improvement means suppression or improvement of dandruff, rough skin, dryness of the scalp, erythema, itching, pimples, and the like.
  • the hair restorer of the present invention can be used to improve the elongation speed of hair shafts or the maximum length of hair shafts. Then, the hair shaft elongation speed can be improved, for example, by about 110% at maximum, and specifically by about 25 to 110%, compared to the hair shaft elongation speed in the standard data of the hair cycle. More specifically, it can be improved by about 33 to 110%.
  • the maximum length of the hair shaft can be improved, for example, by about 49% at maximum, specifically by about 1 to 49%, compared to the maximum length of the hair shaft in the standard data of the hair cycle. More specifically, it can be improved by about 2 to 49%.
  • the hair restorer of the present invention can be used to increase the diameter of hair shafts.
  • the hair restorer of the present invention causes new hairs to grow from pores where hair growth has stopped (no hair shafts protrude from the epidermis) or where there are few hairs, or where hair growth ability has decreased. It can be used to promote hair growth to increase hair number, and in particular can be used to shorten the telogen phase in the hair cycle and/or to restart stopped hair cycles.
  • the hair restorer and scalp care agent of the present invention can be used not only for humans but also for animals such as livestock and pets.
  • a hair growth method and a scalp symptom amelioration method comprising administering an external preparation containing phytosphingosine and adenosine to subjects including humans and non-human animals such as livestock and pets.
  • the VEGF gene is expressed in dermal papilla cells and exhibits effects such as promotion of hair shaft growth, improvement in hair shaft elongation speed, improvement in maximum hair shaft length, and increase in hair shaft diameter in head hair, bristles, eyebrows and/or eyelashes. is said to contribute to Therefore, human dermal papilla cells were used to evaluate the enhancement of VEGF gene expression in each component.
  • Human dermal papilla cells and medium Human dermal papilla cells (catalog number: CA60205a, Caucasian, 29-year-old male, Toyobo Co., Ltd. (Japan)) were purchased and prepared as described in the protocol. We maintained and cultured the cells and performed test evaluations.
  • the FastGene RNA Basic Kit (catalog number: FG-80250, Nippon Genetics Co., Ltd. (Japan)) was used to collect total RNA from the cells.
  • 300 ⁇ L of lysis buffer RL was added per well, and the cells were lysed by pipetting. 300 ⁇ L of 70% ethanol was added to the cell lysate and mixed by pipetting. The sample solution was added to the FastGene RNA binding column and centrifuged at 10000 rpm for 1 minute at room temperature. After discarding the filtrate that passed through the column from the collection tube and returning the FastGene RNA binding column to the original collection tube, 600 ⁇ L of washing buffer RW1 was added to the FastGene RNA binding column and centrifuged at 10000 rpm for 1 minute at room temperature.
  • the FastGene RNA binding column was transferred to a new collection tube and set, 700 ⁇ L of washing buffer RW2 was added to the FastGene RNA binding column, and centrifuged at 10000 rpm for 1 minute at room temperature.
  • the FastGene RNA binding column was transferred to a new collection tube, set, and centrifuged at 15000 rpm for 1 minute at room temperature.
  • the FastGene RNA binding column was transferred to a new collection tube and set, 50 ⁇ L of elution buffer RE was added to the center of the membrane of the FastGene RNA binding column, and centrifuged at 10000 rpm for 1 minute at room temperature to collect the purified RNA.
  • the concentration of the collected RNA was measured with NanoDrop Lite (catalog number: ND-LITE, Thermo Fisher Scientific Co., Ltd.) and stored at -80°C until the next cDNA conversion.
  • FastGene scriptase II cDNA synthesis 5x Ready Mix (catalog number: NE-LS64, Nippon Genetics Co., Ltd. (Japan)) was used for cDNA synthesis.
  • the total RNA produced in a new tube was diluted with RNase-Free Water so that the concentration was 20 ng/mL, and 4 ⁇ L of FastGene scriptase II cDNA synthesis 5 ⁇ Ready Mix was added to 16 ⁇ L of this sample solution and vortexed.
  • a MiniAmp thermal cycler Thermo Fisher Scientific Co., Ltd.
  • the cDNA synthesized by the above method was used for real-time PCR.
  • Add each cDNA template dilution to a predetermined well of a 96-well plate, add THUNDERBIRD SYBR qPCR Mix (catalog number: QPS-201, Toyobo Co., Ltd. (Japan)) and primers, mix, and mix with QuantStudio 7 Flex Real - Gene expression was analyzed with Time PCR System (catalog number: 4485693, Thermo Fisher Scientific Co., Ltd.).
  • As a PCR reaction 40 cycles of 95°C for 5 seconds, 60°C for 30 seconds, and 72°C for 30 seconds were performed.
  • VEGF gene-specific primers used in the test and the GAPDH gene-specific primers used as internal standards are shown below.
  • Primer for detecting VEGF gene expression Forward direction: aggccagcacataggagaga (SEQ ID NO: 1) Reverse: acgcgagtctgtgttttgc (SEQ ID NO: 2)
  • Primer for detecting GAPDH gene expression Forward direction: catccctgcctctactggcgctgcc (SEQ ID NO: 3)
  • the relative expression level of each gene was calculated as follows.
  • the Ct value (PCR cycle number) was calculated from the intersection of the amplification curve of each gene and the threshold line.
  • the value obtained by dividing the Ct value of the target gene by the Ct value of the internal standard GAPDH gene is the relative expression level.
  • phytosphingosine enhances the expression of the VEGF gene in dermal papilla cells, promotes hair shaft growth in hairs such as scalp hair, bristles, eyebrows and/or eyelashes, improves hair shaft elongation speed, and increases the maximum hair shaft length. It was confirmed that it is useful as an active ingredient of a hair restorer and a scalp care agent that have the effect of improving the hair shaft diameter and increasing the diameter of the hair shaft.
  • palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine a mixture of palmitoyl dipeptide-5 diaminohydroxybutyric acid and phytosphingosine are combined with palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine, palmitoyl dipeptide-5 diaminohydroxybutyric acid, or Compared to the case where each phytosphingosine is used alone as an active ingredient, the expression of the VEGF gene in dermal papilla cells is significantly enhanced to further enhance the hair growth effect, and the hair, bristles, eyebrows and / or eyelashes.
  • a hair restorer containing both phytosphingosine and adenosine, or a combination of phytosphingosine and adenosine, as an active ingredient of a hair restorer can be used for hair, bristles, eyebrows and/or eyelashes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cosmetics (AREA)
PCT/JP2022/024018 2021-06-19 2022-06-15 育毛剤 Ceased WO2022265052A1 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN202280054887.5A CN117794509A (zh) 2021-06-19 2022-06-15 育毛剂
KR1020247001997A KR20240023616A (ko) 2021-06-19 2022-06-15 육모제
JP2023530384A JPWO2022265052A1 (https=) 2021-06-19 2022-06-15
US18/571,529 US20240285500A1 (en) 2021-06-19 2022-06-15 Hair growth agent
TW111122674A TW202317076A (zh) 2021-06-19 2022-06-17 育毛劑

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021-102087 2021-06-19
JP2021102087 2021-06-19

Publications (1)

Publication Number Publication Date
WO2022265052A1 true WO2022265052A1 (ja) 2022-12-22

Family

ID=84527115

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/024018 Ceased WO2022265052A1 (ja) 2021-06-19 2022-06-15 育毛剤

Country Status (6)

Country Link
US (1) US20240285500A1 (https=)
JP (1) JPWO2022265052A1 (https=)
KR (1) KR20240023616A (https=)
CN (1) CN117794509A (https=)
TW (1) TW202317076A (https=)
WO (1) WO2022265052A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240023618A (ko) * 2021-06-19 2024-02-22 가부시키가이샤 아쥬반트 홀딩스 육모제

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09227343A (ja) * 1996-02-15 1997-09-02 L'oreal Sa ２−アミノ−１，３−アルカンジオールを含有する、髪抜け遅延および／または髪成長誘発および刺激剤
JP2016520546A (ja) * 2013-04-04 2016-07-14 ピトス カンパニー リミテッド 新規なフィトスフィンゴシン−１−リン酸誘導体、その調製方法、およびそれを含む脱毛の予防、治療、または育毛用組成物
JP2018012738A (ja) * 2012-12-13 2018-01-25 プレシジョン ダーマトロジー インコーポレイテッドＰｒｅｃｉｓｉｏｎ Ｄｅｒｍａｔｏｌｏｇｙ， Ｉｎｃ． ヒアルロン酸の皮膚濃度を増加させるための局所製剤
WO2021075219A1 (ja) * 2019-10-18 2021-04-22 株式会社アジュバンコスメジャパン 育毛剤
WO2022065417A1 (ja) * 2020-09-24 2022-03-31 株式会社アジュバンホールディングス 育毛剤
WO2022107866A1 (ja) * 2020-11-19 2022-05-27 株式会社アジュバンホールディングス 育毛剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4139619A (en) 1976-05-24 1979-02-13 The Upjohn Company 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth
JPH06315021A (ja) 1993-04-28 1994-11-08 Sharp Corp データ光通信装置
JP3006345B2 (ja) 1993-04-30 2000-02-07 住友電装株式会社 フラット・ワイヤハーネスの長さ調節構造
JP3220434B2 (ja) 1998-12-28 2001-10-22 花王株式会社 化粧料
FR2857597B1 (fr) * 2003-07-18 2008-01-25 Inst Europeen Biolog Cellulair Utilisation de conjugues peptidiques pour la preparation de compositions destinees au traitement preventif et curatif de l'alopecie.
ES2397889B1 (es) * 2011-03-25 2014-02-07 Lipotec, S.A. PÉPTIDOS MODULADORES DE PGC-1Alfa.
KR101800956B1 (ko) * 2016-04-04 2018-01-25 주식회사 와이제이테크 파이토스핑고신과 효모추출물을 유효성분으로 포함하는 탈모방지 및 발모촉진용 조성물
CN106075390A (zh) * 2016-07-28 2016-11-09 广东药科大学 一种带正电荷的防脱复合柔性脂质体及其制备方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09227343A (ja) * 1996-02-15 1997-09-02 L'oreal Sa ２−アミノ−１，３−アルカンジオールを含有する、髪抜け遅延および／または髪成長誘発および刺激剤
JP2018012738A (ja) * 2012-12-13 2018-01-25 プレシジョン ダーマトロジー インコーポレイテッドＰｒｅｃｉｓｉｏｎ Ｄｅｒｍａｔｏｌｏｇｙ， Ｉｎｃ． ヒアルロン酸の皮膚濃度を増加させるための局所製剤
JP2016520546A (ja) * 2013-04-04 2016-07-14 ピトス カンパニー リミテッド 新規なフィトスフィンゴシン−１−リン酸誘導体、その調製方法、およびそれを含む脱毛の予防、治療、または育毛用組成物
WO2021075219A1 (ja) * 2019-10-18 2021-04-22 株式会社アジュバンコスメジャパン 育毛剤
WO2022065417A1 (ja) * 2020-09-24 2022-03-31 株式会社アジュバンホールディングス 育毛剤
WO2022107866A1 (ja) * 2020-11-19 2022-05-27 株式会社アジュバンホールディングス 育毛剤

Also Published As

Publication number Publication date
US20240285500A1 (en) 2024-08-29
KR20240023616A (ko) 2024-02-22
JPWO2022265052A1 (https=) 2022-12-22
CN117794509A (zh) 2024-03-29
TW202317076A (zh) 2023-05-01

Similar Documents

Publication Publication Date Title
JP4195763B2 (ja) 毛髪保護作用と毛髪減損の予防性並びにアンドロゲン性脱毛症の外因作用とその結果もたらされる毛髪減損の低下性において、改善された性質を有するヘアローション
WO2022265053A1 (ja) 育毛剤
WO2022265052A1 (ja) 育毛剤
WO2022265054A1 (ja) 育毛剤
WO2022181786A1 (ja) 育毛剤
FR2984129A1 (fr) Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des etats pelliculaires du cuir chevelu
WO2022181785A1 (ja) 育毛剤
JP7291333B2 (ja) 育毛剤
HK40102132A (zh) 育毛剂
KR102035812B1 (ko) 모발 성장 촉진제
HK40092879A (zh) 育毛剂
JP2022551825A (ja) 皮膚微生物叢の多様性を増加させるためのｎ－メチルグリシンの新規化粧使用
US10543227B2 (en) Hair growth composition
HK40101945A (zh) 育毛剂
WO2025084438A1 (ja) 硫酸転移酵素産生促進剤および硫酸転移酵素活性促進剤
JP7853727B2 (ja) ２型アルデヒド脱水素酵素の調節による脱毛または白毛の予防、改善、または治療用組成物
JP2023022204A (ja) 毛乳頭細胞のｆｇｆ－７産生促進剤
FR2968952A1 (fr) Ester d'acide amine n-acyle a titre d'agent apaisant
HK40092880A (zh) 育毛剂
JP3624318B2 (ja) 養毛剤
EP2465581B1 (en) Non-therapeutic use of a composition for promoting hair growth
WO2022124212A1 (ja) 毛髪改善のための組成物
FR3156650A1 (fr) Composition cosmétique comprenant un composé apte à inhiber l’enzyme FIH-1 et un composé apte à inhiber l’enzyme PHD2 pour le traitement de la chute5 des cheveux
FR3156651A1 (fr) Composition cosmétique comprenant du niacinamide et un gingérol pour le traitement de la chute des cheveux
JP2001048756A (ja) 養毛化粧料

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22825040

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2023530384

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2301008230

Country of ref document: TH

WWE Wipo information: entry into national phase

Ref document number: 18571529

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 12023553450

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 20247001997

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020247001997

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 202280054887.5

Country of ref document: CN

122 Ep: pct application non-entry in european phase

Ref document number: 22825040

Country of ref document: EP

Kind code of ref document: A1